文献速递免疫规划卫生政策与健康促进

三带锥蝽病毒样颗粒与克氏锥虫嵌合抗原诱导的抗体应答

Antibodies response induced by recombinant virus-like particles from Triatoma virus and chimeric antigens from Trypanosoma cruzi.
PubMed 文献 · Vaccine · 2021-05-27

本研究在BALB/c小鼠免疫模型中评估三带锥蝽病毒样颗粒(TrV-VLPs)的免疫刺激能力,并分析其与克氏锥虫嵌合重组蛋白(mix-IBMP)联用的免疫原性。结果显示TrV-VLPs在无铝佐剂时优先诱导IgG2b和IgG3型抗体,铝佐剂未干扰抗TrV-VLPs总IgG谱;mix-IBMP与TrV-VLPs混合时总IgG、IgG1和IgG3亚类应答更优。提示TrV-VLPs具疫苗佐剂潜力,克氏锥虫嵌合抗原是恰加斯病疫苗研发的合理策略。

要点

  • TrV-VLPs无铝佐剂时优先诱导IgG2b和IgG3抗体。
  • 铝佐剂未干扰抗TrV-VLPs总IgG抗体谱。
  • mix-IBMP与TrV-VLPs混合时IgG、IgG1和IgG3应答更优。

核心结论

  • TrV-VLPs具有作为疫苗佐剂的潜力。
  • 克氏锥虫嵌合抗原是实验性恰加斯病疫苗研发的合理策略。

研究设计与样本

  • 在BALB/c小鼠免疫模型中,按策略免疫一次或两次,于免疫后15、30、45天采集血清。
  • 用酶联免疫吸附试验(ELISA)检测抗TrV-VLPs总IgG及IgG1、IgG2a、IgG2b、IgG3亚类。

主要发现

  • TrV-VLPs在无铝佐剂时优先诱导IgG2b和IgG3型抗体。
  • 铝佐剂未干扰抗TrV-VLPs的总IgG谱。
  • mix-IBMP与TrV-VLPs混合时总IgG、IgG1和IgG3亚类应答更优。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The infection caused by the protozoan Trypanosoma cruzi affects humans and is called as Chagas disease. Currently, the main measures available to reduce the incidence of this disease are drug treatment and vector control. Traditionally, the development of vaccines occurs mainly through the use of antigenic candidates of the etiologic agent in the form of a vaccine preparation. Virus-like particles (VLPs) are structures analogous to viral capsids composed essentially of structural proteins and are widely used in vaccination protocols because of their immunostimulatory properties. In this context, the objective of this study was to use strategies in a murine immunization model to characterize the immunostimulatory capacity of VLPs from Triatoma virus (TrV-VLPs), analysed in the presence or absence of the aluminium vaccine adjuvant. In parallel, to characterize the immunogenic behaviour of four T. cruzi chimeric recombinant proteins (mix-IBMP) associated with TrV-VLPs or aluminium vaccine adjuvant. METHOD: We immunized BALB/c mice once or twice, depending on the strategy, and collected serum samples at 15, 30 and 45 days after the immunization. Subsequently, serum samples from animals immunized with TrV-VLPs were used to determine total IgG, IgG1, IgG2a, IgG2b and IgG3 anti-TrV-VLPs by enzyme-linked immunosorbent assay (ELISA). RESULTS: Data obtained demonstrate the ability of TrV-VLPs to preferably induce IgG2b and IgG3 type antibodies in the absence of aluminium adjuvant. In fact, the use of aluminium did not interfere with the total IgG profile of anti-TrV-VLPs. Interestingly, mix-IBMP had a better profile of total IgG, IgG1 and IgG3 subclasses when mixed with TrV-VLPs. CONCLUSION: In conclusion, these results suggest the potential of TrV-VLPs as a vaccine adjuvant and the use of T. cruzi chimeric antigens as a rational strategy for the development of vaccines against the experimental model of Chagas disease.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Maria Vasconcelos Queiroz A, Aleksandrovna Yanshina Y, Thays da Silva Rodrigues E, et al. Antibodies response induced by recombinant virus-like particles from Triatoma virus and chimeric antigens from Trypanosoma cruzi. Vaccine. 2021. PMID: 34053789. doi:10.1016/j.vaccine.2021.05.039

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。